Holen Sie sich die Stockscreener-App
48.06
0.33%
0.16
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Increased by Walleye Capital LLC - MarketBeat
Schroder Investment Management Group Purchases 63,517 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
How Crinetics Pharmaceuticals Inc. (6Z4) stock moves in volatile trading sessionsMarket Sentiment Summary & Daily Profit Focused Screening - Newser
Can Crinetics Pharmaceuticals Inc. (6Z4) stock surprise markets with earningsEntry Point & Advanced Technical Signal Analysis - Newser
CRNX SEC FilingsCrinetics Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Why Crinetics Pharmaceuticals Inc. stock could outperform in 2025July 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Is Crinetics Pharmaceuticals Inc. stock gaining market share2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Decheng Capital LLC Cuts Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
How strong dollar benefits Crinetics Pharmaceuticals Inc. (6Z4) stockStock Surge & Weekly High Return Stock Opportunities - Newser
Why Crinetics Pharmaceuticals Inc. (6Z4) stock stays resilient2025 Year in Review & Real-Time Volume Analysis Alerts - Newser
Crinetics doses first patient in phase 1/2 trial of novel cancer drug By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Executive Sells 5,000 Shares - TradingView
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Crinetics Pharmaceuticals (CRNX): Reassessing Valuation After a 3-Month Rebound and DCF Upside Signal - Yahoo Finance
Assessing Crinetics Pharmaceuticals Valuation After Stock Volatility and Pipeline Progress in 2025 - Sahm
Crinetics Pharmaceuticals Says First Patient Dosed in Phase 1/2 Neuroendocrine Tumors Study - MarketScreener
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors - Koreabizwire
Crinetics announces first patient dosed in phase 1/2 trial evaluating CRN09682 - MarketScreener
Crinetics Pharmaceuticals doses first patient in novel tumor treatment trial - Traders Union
Crinetics doses first patient in phase 1/2 trial of novel cancer drug - Investing.com Australia
Crinetics (CRNX) Advances CRN09682 in Clinical Trials for Neuroe - GuruFocus
Crinetics (Nasdaq: CRNX) starts Phase 1/2 BRAVESST2 trial of CRN09682 NDC therapy - Stock Titan
Fisher Asset Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Crinetics Pharmaceuticals Inc. (6Z4) stock prepared for digital transitionQuarterly Risk Review & Free Weekly Watchlist of Top Performers - Newser
XTX Topco Ltd Acquires Shares of 34,013 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Prudential Financial Inc. Has $4.69 Million Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. $CRNX Shares Purchased by American Century Companies Inc. - MarketBeat
(CRNX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Officer Pizzuti Files To Sell 5,000 Of Crinetics Pharmaceuticals Inc [CRNX] - TradingView
Crinetics Pharmaceuticals (CRNX): Evaluating Valuation After Pivotal Phase 3 Milestone for Paltusotine in Carcinoid Syndrome - Sahm
Will Crinetics Pharmaceuticals Inc. stock benefit from green energy trends - BỘ NỘI VỤ
Franklin Resources Inc. Sells 314,143 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year - AOL.com
Crinetics Pharmaceuticals Inc, Inst Holders, 2Q 2019 (CRNX) - 富途牛牛
AXQ Capital LP Acquires New Shares in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Segall Bryant & Hamill LLC Buys 30,243 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharmaceuticals (CRNX): Valuation in Focus After Key Phase 3 Paltusotine Trial Milestone - Sahm
What technical signals suggest for Crinetics Pharmaceuticals Inc. stockTake Profit & Risk Controlled Stock Pick Alerts - newser.com
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Can Crinetics Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Movers & Daily Risk Controlled Trade Plans - newser.com
Is Crinetics Pharmaceuticals Inc. stock a safe haven assetPortfolio Risk Summary & Real-Time Sentiment Analysis - newser.com
Price-Driven Insight from (CRNX) for Rule-Based Strategy - news.stocktradersdaily.com
Crinetics begins Phase 3 trial of oral therapy for carcinoid syndrome - Investing.com Nigeria
Crinetics Pharmaceuticals Begins Phase 3 Trial of Paltusotine in Carcinoid Syndrome - MarketScreener
Crinetics (CRNX) Begins Phase 3 Trial for Paltusotine Treatment - GuruFocus
Crinetics announces first patient randomized in pivotal phase 3 CAREFNDR trial evaluating paltusotine in carcinoid syndrome - MarketScreener
Crinetics begins Phase 3 trial of oral therapy for carcinoid syndrome By Investing.com - Investing.com South Africa
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome - The Manila Times
Crinetics Pharmaceuticals Advances Phase 3 CAREFNDR Trial for Paltusotine in Treating Carcinoid Syndrome - Quiver Quantitative
Crinetics Announces First Patient Randomized in Pivotal - GlobeNewswire
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):